Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-24 @ 6:31 PM
Ignite Modification Date: 2025-12-25 @ 4:01 PM
NCT ID: NCT02904057
Description: The investigator asked the participant for adverse events (AEs) systematically at each visit.
Frequency Threshold: 0
Time Frame: Baseline up to Week 4
Study: NCT02904057
Study Brief: Evaluation of the MJGS Following Radiesse (+) Injection Into the Jawline
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Treatment Group: Radiesse (+) Injectable Implant Participants received Radiesse+Lidocaine Injectable Implant up to 3.0cc volume, once within the jawline region of anterior to posterior boundaries (from the mentum to the earlobe) and superior to inferior boundaries (from the lower cheek to the lower body of the jawline). 0 None 0 19 19 19 View
Control Group: Untreated Participants did not receive jawline treatment. 0 None 0 10 0 10 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Injection site bruising SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.1) View
Injection site swelling SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.1) View
Nodule SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.1) View
Pain SYSTEMATIC_ASSESSMENT General disorders MedDRA (18.1) View
Erythema SYSTEMATIC_ASSESSMENT Skin and subcutaneous tissue disorders MedDRA (18.1) View